Reinforced small intestinal submucosa

Information

  • Patent Grant
  • 7799089
  • Patent Number
    7,799,089
  • Date Filed
    Tuesday, October 10, 2006
    18 years ago
  • Date Issued
    Tuesday, September 21, 2010
    14 years ago
Abstract
Bioprosthetic devices for soft tissue attachment, reinforcement, or construction are provided. The devices comprise a sheet of naturally occurring extracellular matrix and a sheet of synthetic mesh coupled to the naturally occurring extracellular matrix portion.
Description
FIELD OF THE INVENTION

The present invention relates to bioprosthetics and particularly to the use of bioprosthetics for the repair and replacement of connective tissue. More particularly, the present invention relates to the use of a composite bioprosthetic device made up of a synthetic portion and heterologous animal tissue.


BACKGROUND AND SUMMARY OF THE INVENTION

Currently there are multiple patents and publications that describe in detail the characteristics and properties of small intestine submucosa (SIS). See, for example, U.S. Pat. Nos. 5,352,463, 4,902,508, 4,956,178, 5,281,422, 5,372,821, 5,445,833, 5,516,533, 5,573,784, 5,641,518, 5,645,860, 5,668,288, 5,695,998, 5,711,969, 5,730,933, 5,733,868, 5,753,267, 5,755,791, 5,762,966, 5,788,625, 5,866,414, 5,885,619, 5,922,028, 6,056,777, and WO 97/37613, incorporated herein by reference. SIS, in various forms, is commercially available from Cook Biotech Incorporated (Bloomington, Ind.). Further, U.S. Pat. No. 4,400,833 to Kurland and PCT publication having International Publication Number WO 00/16822 provide information related to bioprosthetics and are also incorporated herein by reference.


There are currently many ways in which various types of soft tissues such as ligaments or tendons, for example, are reinforced and/or reconstructed. Suturing the torn or ruptured ends of the tissue is one method of attempting to restore function to the injured tissue. Sutures may also be reinforced through the use of synthetic non-bioabsorbable or bioabsorbable materials. Autografting, where tissue is taken from another site on the patient's body, is another means of soft tissue reconstruction. Yet another means of repair or reconstruction can be achieved through allografting, where tissue from a donor of the same species is used. Still another means of repair or reconstruction of soft tissue is through xenografting in which tissue from a donor of a different species is used.


According to the present invention, a bioprosthetic device for soft tissue attachment, reinforcement, and/or reconstruction is provided. The bioprosthetic device comprises a small intestinal submucosa (SIS) or other naturally occurring extracellular matrix (ECM), formed to include a tissue layer of SIS, and a synthetic portion coupled to the SIS tissue layer. The tissue layer of SIS may also be dehydrated.


In preferred embodiments, the SIS portion of the bioprosthetic device includes a top tissue layer of SIS material and a bottom tissue layer of SIS material coupled to the top tissue layer. The synthetic portion of the bioprosthetic device includes a row of fibers positioned to lie between the top and bottom tissue layers of the SIS portion. The fibers are positioned to lie in a spaced-apart coplanar relation to one another along a length, L, of the SIS portion. The fibers are each formed to include a length L2, where L2 is longer than L so that an outer end portion of each fiber extends beyond the SIS portion in order to anchor the bioprosthetic device to the surrounding soft tissue.


In other embodiments, the synthetic portion of the bioprosthetic device includes a mesh member formed to define the same length, L, as the SIS portion. In yet another embodiment, the synthetic portion of the bioprosthetic device includes a mesh member having a body portion coupled to the SIS portion and outer wing members coupled to the body portion and positioned to extend beyond the length, L, and a width, W, of the SIS portion in order to provide more material for anchoring the bioprosthetic device to the surrounding soft tissue.


SIS is intended to identify small intestine submucosa. While porcine SIS is widely used, it will be appreciated that small intestine submucosa may be obtained from other animal sources, including cattle, sheep, and other warm-blooded mammals. Further, other sources of extracellular matrices from various tissues are known to be effective for tissue remodeling as well. These sources include, but are not limited to, stomach, bladder, alimentary, respiratory, and genital submucosa. See, e.g., U.S. Pat. Nos. 6,171,344, 6,099,567, and 5,554,389, hereby incorporated by reference. Such submucosa-derived matrices comprise highly conserved collagens, glycoproteins, proteoglycans, and glycosaminoglycans. Additionally, other ECMs are known, for example lamina propria and stratum compactum.


For the purposes of this invention, it is within the definition of a naturally occurring ECM to clean, delaminate, and/or comminute the ECM, or even to cross-link the collagen fibers within the ECM. However, it is not within the definition of a naturally occurring ECM to extract and purify the natural fibers and refabricate a matrix material from purified natural fibers. Compare WO 00/16822 A1. Thus, while reference is made to SIS, it is understood that other naturally occurring ECMs are within the scope of this invention.


Fiber is intended to identify a synthetic reinforcement component present within the implant to contribute enhanced mechanical and handling properties. The reinforcement component is preferably in the form of a braided suture or a mesh fabric that is biocompatible. The reinforcement component may be bioabsorbable as well.


The reinforcing component of the tissue implant of the present invention may be comprised of any absorbable or non-absorbable biocompatible material, including textiles with woven, knitted, warped knitted (i.e., lace-like), non-woven, and braided structures. In an exemplary embodiment the reinforcing component has a mesh-like structure. In any of the above structures, mechanical properties of the material can be altered by changing the density or texture of the material. The fibers used to make the reinforcing component can be, for example, monofilaments, yarns, threads, braids, or bundles of fibers. These fibers can be made of any biocompatible material, including bioabsorbable materials such as polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polydioxanone (PDO), trimethylene carbonate (TMC), polyvinyl alcohol (PVA), and copolymers or blends thereof. In an exemplary embodiment, the fibers that comprise the mesh are formed of a polylactic acid and polyglycolic acid copolymer at a 95:5 mole ratio.


Additional features of the present invention will become apparent to those skilled in the art upon consideration of the following description of preferred embodiments of the invention exemplifying the best mode of carrying out the invention as presently perceived.





BRIEF DESCRIPTION OF THE DRAWINGS

The detailed description particularly refers to the accompanying figures in which:



FIG. 1 is a perspective view showing a composite bioprosthetic device of the present invention formed to include a small intestinal submucosa (SIS) portion and a synthetic portion and showing the SIS portion including a top tissue layer of SIS material and a bottom tissue layer of SIS material and further showing the synthetic portion including a row of four fibers positioned to lie in coplanar relation to each other between the top and bottom tissue layers of the SIS portion and positioned to run longitudinally along a length of the SIS portion and extend beyond a first and second end of the SIS portion in order to anchor the bioprosthetic device to surrounding soft tissue;



FIG. 2 is a perspective view similar to FIG. 1 showing an SIS portion of another bioprosthetic device of the present invention being formed to include a top layer, a bottom layer, and two middle layers positioned to lie between the top and the bottom layers and a synthetic device being formed to include three rows of four fibers so that each row is positioned to lie between each of the adjacent tissue layers of the SIS portion so that each fiber is positioned to run longitudinally along a length, L, of the SIS portion;



FIG. 3 is a sectional view taken along line 3-3 of FIG. 2 showing the top, bottom, and middle tissue layers of the SIS portion and also showing the three rows of fibers of the synthetic portion of the bioprosthetic device;



FIG. 4 is a perspective view showing an SIS portion of yet another bioprosthetic device of the present invention being formed to include four tissue layers, similar to FIG. 2, and also showing a synthetic portion of the bioprosthetic device including a first row of multiple fibers positioned to lie between two tissue layers of the SIS portion along a length, L, of the SIS portion and a second row of multiple fibers positioned to lie between two other tissue layers of the SIS portion along a width, W, of the SIS portion;



FIG. 5 is an exploded perspective view of another bioprosthetic device of the present invention showing an SIS portion of the prosthetic device including top, bottom, and middle tissue layers and showing a synthetic portion including a first and a second mesh member positioned to lie between the top and middle tissue layers of and the middle and bottom tissue layers of the SIS portion, respectively;



FIG. 6 is a sectional view of the bioprosthetic device of FIG. 5 showing first and second mesh members “sandwiched” between the tissue layers of the SIS portion of the device;



FIG. 7 is a perspective view showing an SIS portion of another bioprosthetic device being formed to include a top and a bottom tissue layer and further showing a synthetic portion being formed to include a mesh member having a body portion positioned to lie between the top and bottom tissue layers and outer wing portions provided for anchoring the device to surrounding soft tissue; and



FIG. 8 is a perspective view showing an SIS portion of yet another bioprosthetic device being formed to include a circularly shaped top and bottom tissue layers each having a diameter, D1, and further showing a synthetic portion of the device being formed to include a circular mesh member positioned to lie between the top and bottom tissue layers and having a diameter, D2, which is larger than D1 so that an outer rim portion of the mesh member is formed to extend beyond the top and bottom tissue layers for anchoring the bioprosthetic device to the host tissue during surgery.





DETAILED DESCRIPTION OF THE DRAWINGS

A composite bioprosthetic device 10, as shown in FIG. 1, is provided for the purposes of soft tissue attachment, reinforcement, and/or reconstruction. Bioprosthetic device 10 includes a small intestinal submucosa (SIS) portion 12 and a synthetic portion 14. SIS portion 12 is provided to be absorbed into the body and replaced by host tissue. SIS portion 12 acts as a scaffold for tissue ingrowth and remodeling. Synthetic portion 14 of bioprosthetic device 10 provides additional initial mechanical strength to bioprosthetic device 10. Because device 10 includes SIS portion 12 and synthetic portion 14, bioprosthetic device 10 is provided with a differential in biodegradation and bioremodeling rates. Synthetic portion 14, for example, can be configured to degrade at a slower rate than SIS portion 12. Further, synthetic portion 14 may act as an anchor to couple bioprosthetic device 10 to the surrounding soft tissue (not shown) during surgery.


SIS portion 12 of bioprosthetic device 10, as shown in FIG. 1, includes a top tissue layer 16 and a bottom tissue layer 18 coupled to top tissue layer 16 through a dehydration process. Although top and bottom tissue layers 16, 18 are provided in bioprosthetic device 10 shown in FIG. 1, it is within the scope of this disclosure, as will be described in more detail later, to include SIS portions 12 having any number of tissue layers. It is also included within the scope of this disclosure to provide perforated tissue layers or any other physical configuration of SIS. See FIGS. 2-4, for example. Further, it is within the scope of this disclosure to define top and bottom tissue layers 16, 18 as including multiple tissue layers each. In preferred embodiments, for example, top and bottom tissue layers 16, 18 each include three to four layers of SIS tissue. SIS portion 12 further includes a first end 20, a second end 22 spaced-apart from first end 20, and sides 24 coupled to and positioned to lie between first and second ends 20, 22. A length, L, is defined as the distance between first end 20 and second end 22 and a width, W, is defined as the distance between sides 24.


Synthetic portion 14 of bioprosthetic device 10 includes row 26 of four fibers 28, as shown in FIG. 1. Fibers 28 are positioned to lie along length L between top and bottom tissue layers 16, 18 and are further positioned to lie in coplanar relation to one another. When making bioprosthetic device 10, fibers 28 of synthetic portion 14 are placed between top and bottom tissue layers 16, 18 prior to dehydration. Although row 26 of four fibers 28 is provided in bioprosthetic device 10 shown in FIG. 1, it is within the scope of this disclosure to include synthetic portions 14 formed to include any number of rows 26 having any number of fibers 28. It is further within the scope of this disclosure to include fibers 28 made from bioabsorbable and non-bioabsorbable materials. For example, it is within the scope of this disclosure to include fibers 28 made from polylactic acid (PLA) or polyglycolic (PGA) acid, a combination of the two, Panacryl™ absorbable suture (Ethicon, Inc, Somerville, N.J.), other bioabsorbable materials, nylon, polyethylene, Kevlar™, Dacron™, PTFE, carbon fiber, or other non-bioabsorbable materials.


As shown in FIG. 1, each fiber 28 of bioprosthetic device 10 includes two outer end portions 30 a middle portion 32 coupled to and positioned to lie between outer end portions 30. Middle portion 32 is positioned to lie between top tissue layer 16 and bottom tissue layer 18 of SIS portion 12. Middle portion 32 of fibers 28 helps to provide strength along length, L, of bioprosthetic device 10. One or more outer end portions 30 of fibers 28 can be used for anchoring bioprosthetic device 10 to surrounding soft tissue (not shown). The combination of SIS portion 12 and fibers 28 further provide bioprosthetic device 10 with differential biodegradation rates. For example, fibers 28 of synthetic portion 14 can be made to be non-bioabsorbable or can be made with material that absorbs into the body at a slower rate than SIS portion 12. Uses for bioprosthetic device 10 shown in FIG. 1 include, but are not limited to, ligament or tendon repair.


An alternate bioprosthetic device 110 is shown in FIGS. 2 and 3. Bioprosthetic device 110 include an alternate SIS portion 112 of having top tissue layer 16, bottom tissue layer 18, and two middle tissue layers 115. Top, bottom, and middle tissue layers 16, 18, 115 include one or more layers of SIS tissue each. SIS portion 112, similar to SIS portion 12, also includes a first end 20, a second end 22 spaced-apart from first end 20, and sides 24. Bioprosthetic device 110 further includes an alternate synthetic portion 114 having three rows 26 of four fibers 28. One row 26 is positioned to lie between top tissue layer 16 and one of the middle tissue layers 115. Another row 26 is positioned to lie between the two middle tissue layers 115, and the final row 26 of fibers 28 is positioned to lie between another one of the middle tissue layers 115 and bottom tissue layer 16, as shown in FIG. 3. Fibers 28 of bioprosthetic device 110, similar to fibers 28 of bioprosthetic device 10, are positioned to lie along length, L, of SIS portion 112.


Although fibers 28 of bioprosthetic devices 10, 110 are positioned to lie along length, L, of each respective SIS portion 12, 112, it is within the scope of this disclosure to include a synthetic portion 214 of an alternate bioprosthetic device 210, as shown in FIG. 4, having multi-directional fibers 28 positioned to lie along a length, L, of an SIS portion 212 and along width, W, of SIS portion 212. Synthetic portion 214 of bioprosthetic device 210 includes a first row 226 having seventeen fibers 28 positioned to lie along length, L, of SIS portion 212. Synthetic portion 214 further includes a second row 227 having eighteen fibers 28 positioned to lie along width, W, of SIS portion 212 so that the fibers 28 of first row 226 and second row 227 are positioned to lie orthogonally with respect to each other. Although rows 226 and 227 are positioned to lie in orthogonal relation to one another, it is within the scope of this disclosure to include synthetic portion 214 having first and second rows 226 and 227 that lie at any angular relation to one another. It is also within the scope of this disclosure to include rows 226 and 227 each having any number of fibers 28.


Similar to bioprosthetic device 110 shown in FIG. 2, bioprosthetic device 210 includes a top tissue layer 216, a bottom tissue layer 218, and two middle tissue layers 215, positioned to lie between top and bottom tissue layers 216, 218. As mentioned before, top, bottom, and middle tissue layers 216, 218, 215 are each formed to include one or more layers of SIS tissue. Although SIS portion 212 of bioprosthetic device 210 is shown to include four tissue layers, it is within the scope of the disclosure to include bioprosthetic device 210 having any number of tissue layers. As shown in FIG. 4, first row 226 is positioned to lie between top tissue layer 216 and one of the two middle tissue layers 215 positioned to lie adjacent to top tissue layer 216. Second row 227 is positioned to lie between the other middle tissue layer 215 and bottom tissue layer 218. It is within the scope of this disclosure, however, to include rows 226, 227 positioned to lie between any tissue layer of device 210.


Yet another bioprosthetic device 310 is shown in FIGS. 5 and 6. Bioprosthetic device 310 is similar to devices, 10, 110, and 210 and includes an SIS portion 312 having a top tissue layer 316, a bottom tissue layer 318, and a middle tissue layer 315 positioned to lie between top and bottom tissue layers 316, 318. Top, bottom, and middle tissue layers 316, 318, 315 each include one or more layers of SIS tissue. Bioprosthetic device 310 further includes a synthetic portion 314 including first mesh member 320 and second mesh member 322. It is within the scope of this disclosure to include any type of synthetic mesh member. For example, bioabsorbable and/or non-bioabsorbable mesh members 320, 322 made of either woven or non-woven PGA and/or PLA mixtures are included within the scope of disclosure of this invention. First mesh member 320 is coupled to and positioned to lie between top tissue layer 316 and middle tissue layer 315 and second mesh member 322 is coupled to and positioned to lie between middle tissue layer 315 and bottom tissue layer 318, as shown in FIGS. 5 and 6. As shown, each of the first and second mesh members 320, 322 has a length, L, and a width, W, approximately equal to length, L, and width, W, of tissue layers 315, 316, 318, of SIS portion 312. However, in some embodiments, it may be preferable for the mesh to be slightly smaller.


In FIG. 5, second mesh member 322 is shown partially coated in comminuted SIS 340. Comminuted SIS may be used to fill the interstices of second mesh member 322 to provide a stronger device. Other means for reinforcing bioprosthetic device 10 may be employed, including suturing or tacking the various layers together. Further, while comminuted SIS is discussed with respect to the embodiment shown in FIG. 5, it is understood that comminuted SIS may be used to coat the mesh or fibers for any embodiment.


Another embodiment of the present invention includes a bioprosthetic device 410 having a synthetic portion 414 including a mesh member 420, as shown in FIG. 7. Similar to the previously mentioned devices, bioprosthetic device 410 includes an SIS portion 412 having a top tissue layer 416 and a bottom tissue layer 418 coupled to top tissue layer 416. Top and bottom tissue layers 416, 418 each include one or more layers of SIS tissue. Mesh member 420 includes a central body portion (not shown) and outer wing portions 430, as shown in FIG. 7. Outer wing portions 430 are extensions of the central body portion. Although four outer wing portions 430 are shown in FIG. 7, it is within the scope of this disclosure to include a mesh member having a body portion and any number of wing portions 430 coupled to the body portion. The central body portion of mesh member 420 is formed to include a length and a width equal to length, L, and width, W, of SIS portion 412. The central body portion is coupled to and positioned to lie between top tissue layer 416 and bottom tissue layer 418 of SIS portion 420. Each wing portion 430 is coupled to the central body portion of mesh member 420 and is positioned to extend beyond the length, L, and width, W, of SIS portion 412, as shown in FIG. 7. As mentioned before, outer wing portions 430 are extensions of the central body portion. Wing portions 430 provide additional material for anchoring bioprosthetic device 410 to the surrounding soft tissue. Because outer wing portions 430 extend beyond central body portion of mesh member 420, mesh member 420 has a length and a width greater than length, L, and width, W, of SIS portion 412.


Yet another embodiment of the present invention is shown in FIG. 8 showing a bioprosthetic device 510 similar to bioprosthetic device 410, described above. Bioprosthetic device 510 includes an SIS portion 512 and a synthetic portion 514 coupled to SIS portion 512. SIS portion 512 includes a top tissue layer 516 which is circular in shape and a bottom tissue layer 518 which is also circular in shape. Each of the top and bottom tissue layers 516, 518 include one or more layers of SIS tissue. Top and bottom tissue layers 516, 518 each have a diameter, D1. The synthetic portion 514 of bioprosthetic device 510 includes a mesh member 520 coupled to and positioned to lie between top and bottom tissue layers 516, 518. Mesh member 520 is circular in shape and has a diameter, D2, which is greater than diameter, D1, of synthetic portion 512. Therefore, as shown in FIG. 8, an outer rim portion 530 of mesh member 520 is provided. Similar to outer wing portions 430 of bioprosthetic device 410, shown in FIG. 7, outer rim portion 530 of bioprosthetic device 510 provides additional material for anchoring bioprosthetic device 510 to the surrounding soft tissue during surgery.


Although various embodiments have been described in detail above, it is within the scope of this disclosure to include any bioprosthetic device having an SIS portion and a synthetic portion coupled to the SIS portion in order to provide improved initial mechanical strength of the bioprosthetic device, to obtain desired differential biodegradation and bioremodeling rates, and to provide improved anchoring means of the device to the host tissue. For example, FIGS. 1-8 show the SIS portion including SIS tissue layers in the form of sheets. It is within the scope of this disclosure, however, to further define the SIS portion to include sheets, perforated sheets, or any other physical configuration of SIS. It is also within the scope of this disclosure to include the synthetic portion comprising Prolene™ (Ethicon, Inc, Somerville, N.J.) meshes and/or sutures, Vicryl™ (Ethicon, Inc, Somerville, N.J.) meshes and/or sutures, Mersilene™ (Ethicon, Inc, Somerville, N.J.) meshes, PDS II™ (Ethicon, Inc., Somerville, N.J.) meshes or sutures, Panacryl™ (Ethicon, Inc., Somerville, N.J.) meshes or sutures, and Monocryl™ meshes or sutures, for example. Further it is within the scope of this disclosure to include any bioprosthetic devices where the SIS portion includes any number of tissue layers made from SIS and where multiple tissue layers are positioned to lie between each layer of fibers and/or mesh of the synthetic portion. The SIS layers may be dehydrated prior to or subsequent to assembly of the device.


It is also within the scope of this disclosure to include bioprosthetic device where the synthetic portion is either bioabsorbable or non-bioabsorbable and includes any number of fibers and/or any number of mesh members, as described above. Although FIGS. 1-4 show the synthetic portion being defined by fibers, it is within the scope of the disclosure for the synthetic portion to also be defined by fibers or fibrous materials, for example. Further, any shape and/or orientation of the SIS portion and the synthetic portion of the bioprosthetic device is within the scope of this disclosure; FIGS. 1-8 are merely examples of various embodiments of the present invention.


Example 1

Sheets of clean, disinfected porcine SIS material were obtained as described in U.S. Pat. Nos. 4,902,508 and 4,956,178. Ten strips 3.5 inches wide and 6 inches long were cut. The strips were hydrated by placing in RO water, at room temperature, for 5 minutes.


To assemble the implant, five SIS strips were placed on top of each other, while ensuring no air bubbles were trapped between the strips. A knitted Panacryl™ mesh 2 inches wide and 5 inches long, was placed centrally on the 5-layer thick SIS strip. The mesh had been pretreated to remove any traces of oil or other contaminants due to handling. This was done by a series of rinses, each 2 minutes long, in 100%, 90%, 80%, 70% ethanol (200 proof) in RO water, followed by a final 5 minute in RO water. Subsequently, a second 5-layer thick strip of SIS was assembled and placed to sandwich the mesh between the two SIS strips.


The implant was dried under vacuum pressure using a gel drier system (Model FB-GD-45, Fisher Scientific, Pittsburgh, Pa.) for 3 hours. The gel drier bed temperature was set at 30° C. for the procedure. This drying procedure results in “squeezing out” of the bulk water in the implant and also reduces the amount of bound water within the tissue, resulting in a final moisture of between 7%-8%. This process also results in a physical crosslinking between the laminates of SIS and between the mesh and adjacent SIS laminates.


Non-reinforced SIS strips were made in the same way as described, except that no mesh material was placed between the strips of SIS.


Example 2

A soaking test was performed to test resistance to delamination. Implants made as specified in Example 1 (both reinforced and non-reinforced) were cut into several strips 1 cm wide by 5 cm long, using a #10 scalpel blade. The strips were immersed in RO water, at room temperature for 1, 2, 5, 10, 20, 30, or 60 minutes. Delamination was detected at the edges of the implants by direct visual observation. All implants showed obvious signs of delamination at 1 hour. In non-reinforced implants, delamination was first visually observed between 40-60 minutes, whereas in the reinforced samples delamination was apparent between 20-30 minutes.


Example 3

This example illustrates the enhanced mechanical properties of a construct reinforced with absorbable mesh. Preparation of three-dimensional elastomeric tissue implants with and without a reinforcement in the form of a biodegradable mesh are described. While a foam is used for the elastomeric tissue in this example, it is expected that similar results will be achieved with an ECM and a biodegradable mesh.


A solution of the polymer to be lyophilized to form the foam component was prepared in a four step process. A 95/5 weight ratio solution of 1,4-dioxane/(40/60 PCL/PLA) was made and poured into a flask. The flask was placed in a water bath, stirring at 70° C. for 5 hrs. The solution was filtered using an extraction thimble, extra coarse porosity, type ASTM 170-220 (EC) and stored in flasks.


Reinforcing mesh materials formed of a 90/10 copolymer of polyglycolic/polylactic acid (PGA/PLA) knitted (Code VKM-M) and woven (Code VWM-M), both sold under the tradename VICRYL were rendered flat by ironing, using a compression molder at 80° C./2 min. After preparing the meshes, 0.8-mm shims were placed at each end of a 15.3×15.3 cm aluminum mold, and the mesh was sized (14.2 mm) to fit the mold. The mesh was then laid into the mold, covering both shims. A clamping block was then placed on the top of the mesh and the shim such that the block was clamped properly to ensure that the mesh had a uniform height in the mold. Another clamping block was then placed at the other end, slightly stretching the mesh to keep it even and flat.


As the polymer solution was added to the mold, the mold was tilted to about a 5 degree angle so that one of the non-clamping sides was higher than the other. Approximately 60 ml of the polymer solution was slowly transferred into the mold, ensuring that the solution was well dispersed in the mold. The mold was then placed on a shelf in a Virtis (Gardiner, N.Y.), Freeze Mobile G freeze dryer. The following freeze drying sequence was used: 1) 20° C. for 15 minutes; 2) −5° C. for 120 minutes; 3) −5° C. for 90 minutes under vacuum 100 milliTorr; 4) 5° C. for 90 minutes under vacuum 100 milliTorr; 5) 20° C. for 90 minutes under vacuum 100 milliTorr. The mold assembly was then removed from the freezer and placed in a nitrogen box overnight. Following the completion of this process the resulting implant was carefully peeled out of the mold in the form of a foam/mesh sheet.


Nonreinforced foams were also fabricated. To obtain non-reinforced foams, however, the steps regarding the insertion of the mesh into the mold were not performed. The lyophilization steps above were followed.


Example 4

Lyophilized 40/60 polycaprolactone/polylactic acid, (PCL/PLA) foam, as well as the same foam reinforced with an embedded VICRYL knitted mesh, were fabricated as described in Example 3. These reinforced implants were tested for suture pull-out strength and compared to non-reinforced foam prepared following the procedure of Example 3.


For the suture pull-out strength test, the dimensions of the specimens were approximately 5 cm×9 cm. Specimens were tested for pull-out strength in the wale direction of the mesh (knitting machine axis). A size 0 polypropylene monofilament suture (Code 8834H), sold under the tradename PROLENE (by Ethicon, Inc., Somerville, N.J.) was passed through the mesh 6.25 mm from the edge of the specimens. The ends of the suture were clamped into the upper jaw and the mesh or the reinforced foam was clamped into the lower jaw of an Instron model 4501 (Canton, Mass.). The Instron machine, with a 20 lb load cell, was activated using a cross-head speed of 2.54 cm per minute. The ends of the suture were pulled at a constant rate until failure occurred. The peak load (lbs.) experienced during the pulling was recorded.


The results of this test are shown below in Table 1.









TABLE 1







Suture Pull-Out Data (lbs.)












Time
Foam
Mesh
Foamed Mesh







0 Day
0.46
5.3 +/− 0.8
5.7 +/− 0.3



7 Day*

4.0 +/− 1.0
5.0 +/− 0.5







*exposed for 7 days to phosphate buffered saline at 37° C. in a temperature controlled water bath.






These data show that a reinforced foam has improved pull-out strength verses either foam or mesh alone.


Although the invention has been described in detail with reference to certain preferred embodiments, variations and modifications exist within the scope and spirit of the invention as described and defined in the following claims.

Claims
  • 1. A bioprosthetic device comprising: a sheet of naturally occurring extracellular matrix; anda sheet of bioabsorbable synthetic mesh coupled to the sheet of naturally occurring extracellular matrix, wherein the sheet of synthetic mesh has a rate of absorption that is slower than a rate of absorption of the sheet of naturally occurring extracellular matrix.
  • 2. The bioprosthetic device of claim 1, wherein the naturally occurring extracellular matrix is selected from the group consisting of intestine submucosa, stomach submusoca, bladder submucosa, alimentary submucosa, respiratory sumucosa and genital submucosa.
Parent Case Info

This application is a continuation of U.S. patent application Ser. No. 10/656,345, filed Sep. 5, 2003, now U.S. Pat. No. 7,160,333, which is a continuation of U.S. patent application Ser. No. 09/918,116, filed Jul. 30, 2001, now U.S. Pat. No. 6,638,312, which claims priority under 35 U.S.C. 119(e) to U.S. Provisional Application Ser. No. 60/223,399, filed Aug. 4, 2000, each of which is expressly incorporated by reference herein.

US Referenced Citations (178)
Number Name Date Kind
3272204 Artandi et al. Sep 1966 A
3562820 Braun Feb 1971 A
4352463 Baker Oct 1982 A
4400833 Kurland Aug 1983 A
4418691 Yannas et al. Dec 1983 A
4610397 Fischer et al. Sep 1986 A
4642120 Nevo et al. Feb 1987 A
4703108 Silver et al. Oct 1987 A
4873976 Schreiber Oct 1989 A
4880429 Stone Nov 1989 A
4902508 Badylak et al. Feb 1990 A
5281422 Badylak et al. Jan 1994 A
5306311 Stone et al. Apr 1994 A
5320633 Allen et al. Jun 1994 A
5350583 Yoshizato et al. Sep 1994 A
5352463 Badylak et al. Oct 1994 A
5372821 Badylak et al. Dec 1994 A
5374268 Sander Dec 1994 A
5376118 Kaplan et al. Dec 1994 A
5380334 Torrier et al. Jan 1995 A
5445833 Badylak et al. Aug 1995 A
5447940 Harvey et al. Sep 1995 A
5460962 Kemp Oct 1995 A
5464929 Bezwada et al. Nov 1995 A
5479033 Baca et al. Dec 1995 A
5514181 Light et al. May 1996 A
5516533 Badylak et al. May 1996 A
5554389 Badylak et al. Sep 1996 A
5569252 Justin et al. Oct 1996 A
5573784 Badylak et al. Nov 1996 A
5591234 Kirsch Jan 1997 A
5593441 Lichtenstein et al. Jan 1997 A
5595621 Light et al. Jan 1997 A
5601558 Torrie et al. Feb 1997 A
5632745 Schwartz May 1997 A
5641518 Badylak et al. Jun 1997 A
5645860 Knapp, Jr. et al. Jul 1997 A
5660225 Saffran Aug 1997 A
5668288 Storey et al. Sep 1997 A
5669912 Spetzler Sep 1997 A
5677355 Shalaby et al. Oct 1997 A
5681353 Li et al. Oct 1997 A
5693085 Buirge et al. Dec 1997 A
5695998 Badylak et al. Dec 1997 A
5702462 Oberlander Dec 1997 A
5711969 Patel et al. Jan 1998 A
5759205 Valentini Jun 1998 A
5762966 Knap et al. Jun 1998 A
5769899 Schwartz et al. Jun 1998 A
5773577 Cappello Jun 1998 A
5788625 Plouhar et al. Aug 1998 A
5795353 Felt Aug 1998 A
5800537 Bell Sep 1998 A
5830708 Naughton Nov 1998 A
5834232 Bishop Nov 1998 A
5842477 Naughton et al. Dec 1998 A
5847012 Shalaby et al. Dec 1998 A
5855613 Antanavich et al. Jan 1999 A
5855619 Caplan et al. Jan 1999 A
5863551 Woerly Jan 1999 A
5866414 Badylak et al. Feb 1999 A
5885619 Patel et al. Mar 1999 A
5899939 Boyce et al. May 1999 A
5916265 Hu Jun 1999 A
5922028 Plouhar et al. Jul 1999 A
5939323 Valentini et al. Aug 1999 A
5948429 Bell et al. Sep 1999 A
5954723 Spetzler Sep 1999 A
5954747 Clark Sep 1999 A
5955100 Bosslet et al. Sep 1999 A
5958874 Clark et al. Sep 1999 A
5968096 Whitson et al. Oct 1999 A
5969020 Shalaby et al. Oct 1999 A
5971987 Huxel et al. Oct 1999 A
5980524 Justin et al. Nov 1999 A
5981825 Brekke Nov 1999 A
5989269 Vibe-Hansen et al. Nov 1999 A
5989280 Euteneuer et al. Nov 1999 A
5993475 Lin et al. Nov 1999 A
5993844 Abraham et al. Nov 1999 A
5997575 Whitson et al. Dec 1999 A
6017348 Hart et al. Jan 2000 A
6027744 Vacanti et al. Feb 2000 A
6042610 Li et al. Mar 2000 A
6051750 Bell Apr 2000 A
6056752 Roger May 2000 A
6056777 McDowell May 2000 A
6056778 Grafton et al. May 2000 A
6060640 Pauley et al. May 2000 A
6068648 Cole et al. May 2000 A
6077989 Kandel et al. Jun 2000 A
6080194 Pachence et al. Jun 2000 A
6093201 Cooper et al. Jul 2000 A
6098347 Jaeger et al. Aug 2000 A
6099567 Badylak et al. Aug 2000 A
6110212 Gregory Aug 2000 A
6126686 Badylak et al. Oct 2000 A
6146385 Torrie et al. Nov 2000 A
6152935 Kammerer et al. Nov 2000 A
6153292 Bell et al. Nov 2000 A
6156044 Kammerer et al. Dec 2000 A
6165225 Antanavich et al. Dec 2000 A
6171344 Atala Jan 2001 B1
6176880 Plouhar et al. Jan 2001 B1
6179840 Bowman Jan 2001 B1
6179872 Bell et al. Jan 2001 B1
6187039 Hiles et al. Feb 2001 B1
6206931 Cook et al. Mar 2001 B1
6214049 Gayer et al. Apr 2001 B1
6224892 Searle May 2001 B1
6235057 Roger et al. May 2001 B1
6242247 Rieser et al. Jun 2001 B1
6251143 Schwartz et al. Jun 2001 B1
6251876 Bellini et al. Jun 2001 B1
6258124 Darois et al. Jul 2001 B1
6264702 Ory et al. Jul 2001 B1
6265333 Dzenis et al. Jul 2001 B1
6270530 Eldridge et al. Aug 2001 B1
6273893 McAllen, III et al. Aug 2001 B1
6280473 Lemperle et al. Aug 2001 B1
6283980 Vibe-Hansen et al. Sep 2001 B1
6288043 Spiro et al. Sep 2001 B1
6290711 Caspari et al. Sep 2001 B1
6293961 Schwartz et al. Sep 2001 B2
6294041 Boyce et al. Sep 2001 B1
6306156 Clark Oct 2001 B1
6306159 Schwartz et al. Oct 2001 B1
6306177 Felt et al. Oct 2001 B1
6319258 McAllen, III et al. Nov 2001 B1
6319271 Schwartz et al. Nov 2001 B1
6326025 Sigler et al. Dec 2001 B1
6333029 Vyakarnam et al. Dec 2001 B1
6334872 Termin et al. Jan 2002 B1
6355699 Vyakarnam et al. Mar 2002 B1
6358284 Fearnot et al. Mar 2002 B1
6364884 Bowman et al. Apr 2002 B1
6371958 Overaker Apr 2002 B1
6373221 Koike et al. Apr 2002 B1
6379367 Vibe-Hansen et al. Apr 2002 B1
6379710 Badylak Apr 2002 B1
6383221 Scarborough et al. May 2002 B1
6387693 Rieser et al. May 2002 B2
6409764 White et al. Jun 2002 B1
6440444 Boyce et al. Aug 2002 B2
6451032 Ory et al. Sep 2002 B1
6458158 Anderson et al. Oct 2002 B1
6458383 Chen et al. Oct 2002 B2
6464729 Kandel Oct 2002 B1
6497650 Nicolo Dec 2002 B1
6517564 Grafton et al. Feb 2003 B1
6572650 Abraham et al. Jun 2003 B1
6592623 Bowlin et al. Jul 2003 B1
6638312 Plouhar et al. Oct 2003 B2
6652872 Nevo et al. Nov 2003 B2
6666892 Hiles et al. Dec 2003 B2
6692499 Tormala et al. Feb 2004 B2
6812221 McKeehan et al. Nov 2004 B2
6840962 Vacanti et al. Jan 2005 B1
7160333 Plouhar et al. Jan 2007 B2
20010024658 Chen et al. Sep 2001 A1
20010043943 Coffey Nov 2001 A1
20020019649 Sikora et al. Feb 2002 A1
20020038151 Plouhar et al. Mar 2002 A1
20020048595 Geistlich et al. Apr 2002 A1
20020099448 Hiles Jul 2002 A1
20020173806 Giannetti et al. Nov 2002 A1
20030014126 Patel et al. Jan 2003 A1
20030021827 Malaviya et al. Jan 2003 A1
20030023316 Brown et al. Jan 2003 A1
20030032961 Pelo et al. Feb 2003 A1
20030033021 Plouhar et al. Feb 2003 A1
20030033022 Plouhar et al. Feb 2003 A1
20030036797 Malaviya et al. Feb 2003 A1
20030036801 Schwartz et al. Feb 2003 A1
20030044444 Malaviya et al. Mar 2003 A1
20030049299 Malaviya et al. Mar 2003 A1
20030212447 Euteneuer et al. Nov 2003 A1
20040143344 Malaviya et al. Jul 2004 A1
Foreign Referenced Citations (33)
Number Date Country
0466105 Jan 1992 EP
0 734 736 Oct 1996 EP
2215209 Sep 1989 GB
11319068 Nov 1999 JP
2000210311 Aug 2000 JP
2000210376 Aug 2000 JP
WO 9009769 Sep 1990 WO
WO 9411008 May 1994 WO
WO 9505083 Feb 1995 WO
WO 9522301 Aug 1995 WO
WO 9506439 Sep 1995 WO
WO 9532623 Dec 1995 WO
WO 9624661 Aug 1996 WO
9715195 May 1997 WO
WO 9737613 Oct 1997 WO
WO 9806445 Feb 1998 WO
9822154 May 1998 WO
WO 9822158 May 1998 WO
WO 9822158 May 1998 WO
WO 9830167 Jul 1998 WO
WO 9834569 Aug 1998 WO
WO 9903979 Jan 1999 WO
9919005 Apr 1999 WO
WO 9943786 Sep 1999 WO
WO 9947188 Sep 1999 WO
WO 0016822 Mar 2000 WO
WO 0024437 May 2000 WO
WO 0024437 May 2000 WO
PCT0032749 Jun 2000 WO
WO 0032250 Jun 2000 WO
WO 0048550 Aug 2000 WO
WO 0072782 Dec 2000 WO
WO 03007790 Jan 2003 WO
Related Publications (1)
Number Date Country
20070129811 A1 Jun 2007 US
Provisional Applications (1)
Number Date Country
60223399 Aug 2000 US
Continuations (2)
Number Date Country
Parent 10656345 Sep 2003 US
Child 11548071 US
Parent 09918116 Jul 2001 US
Child 10656345 US